Navigation Links
Study adds to evidence daily aspirin linked to lower cancer mortality
Date:8/10/2012

ATLANTA August 10, 2012A large new observational study finds more evidence of an association between daily aspirin use and modestly lower cancer mortality, but suggests any reduction may be smaller than that observed in a recent analysis. The study, appearing early online in the Journal of the National Cancer Institute (JNCI), provides additional support for a potential benefit of daily aspirin use for cancer mortality, but the authors say important questions remain about the size of the potential benefit.

A recent analysis pooling results from existing randomized trials of daily aspirin for prevention of vascular events found an estimated 37% reduction in cancer mortality among those using aspirin for five years or more. But uncertainty remains about how much daily aspirin use may lower cancer mortality, as the size of this pooled analysis was limited and two very large randomized trials of aspirin taken every other day found no effect on overall cancer mortality.

For the current study, American Cancer Society researchers led by Eric J. Jacobs, Ph.D., analyzed information from 100,139 predominantly elderly participants in the Cancer Prevention Study II Nutrition Cohort who reported aspirin use on questionnaires, did not have cancer at the start of the study, and were followed for up to 11 years. They found daily aspirin use was associated with an estimated 16% lower overall risk of cancer mortality, both among people who reported taking aspirin daily for at least five years and among those who reported shorter term daily use. The lower overall cancer mortality was driven by about 40% lower mortality from cancers of the gastrointestinal tract (such as esophageal, stomach, and colorectal cancer) and about 12% lower mortality from cancers outside the gastrointestinal tract.

The reduction in cancer mortality observed in the current study is considerably smaller than the 37% reduction reported in the recent pooled analysis of randomized trials. The authors note that their study was observational, not randomized, and therefore could have underestimated or overestimated potential effects on cancer mortality if participants who took aspirin daily had different underlying risk factors for fatal cancer than those who did not. However, the study's large size is a strength in determining how much daily aspirin use might lower cancer mortality.

"Expert committees that develop clinical guidelines will consider the totality of evidence about aspirin's risks and benefits when guidelines for aspirin use are next updated," said Dr. Jacobs. "Although recent evidence about aspirin use and cancer is encouraging, it is still premature to recommend people start taking aspirin specifically to prevent cancer. Even low-dose aspirin can substantially increase the risk of serious gastrointestinal bleeding. Decisions about aspirin use should be made by balancing the risks against the benefits in the context of each individual's medical history. Any decision about daily aspirin use should be made only in consultation with a health care professional."


'/>"/>

Contact: Andrew Becker
andrew.becker@cancer.org
917-673-7728
American Cancer Society
Source:Eurekalert

Related medicine news :

1. Dental Woes Abound for Developmentally Disabled: Study
2. Babies of Heavy Moms Grow Slower: Study
3. Exergames Can Help Inactive Folks Get Moving: Study
4. Workers With Disabilities More Prone to Injuries: Study
5. Pay Attention in Preschool, Graduate From College: Study
6. Statins Heart Benefits Outweigh Diabetes Risk: Study
7. Male Diners Tip Better When Waitress Wears Red: Study
8. Birds Songs Reflect Changing Weather Patterns: Study
9. Source of conflict: Study finds factors that can shape divorced mothers co-parenting experiences
10. Two Languages Better Than One for Kids Brains: Study
11. Rhode Island Hospital study: Bariatric patients with obstructive sleep apnea fail to show symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions ... definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... this summer’s edition of “Vision & Hearing,” advocating for active, healthy lifestyles and ... on resources available for individuals with hearing impairments and shares the latest innovations ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... handling handheld devices. Through an educational webinar, they will present the line of ... chance to learn how easy you can automate everyday pipetting tasks. , Ideal ...
(Date:8/18/2017)... ... August 18, 2017 , ... Hernandez Insurance Agencies, a northern ... the greater DC region, is inaugurating a “New Leash On Life” charity initiative ... training them to be companions for veterans in need. , The Semper K9 ...
(Date:8/18/2017)... ... 18, 2017 , ... Moore Insurance, a Houston area agency ... is launching a regional charity effort to provide publicity assistance and generate donations ... Tumor Foundation (PBTF) has raised nearly $30 million in donations that has been ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
(Date:7/27/2017)... July 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... for the second-quarter 2017 and updated financial guidance for ... Second-Quarter 2017 Highlights Reported net sales ... the prior-year quarter. Net sales at constant currency (organic) ... EPS was $0.51, compared to $0.60 in the prior-year ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: